AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CLINUVEL PHARMACEUTICALS LTD

11.060

-0.670-5.71%

Volume:120.21K

Turnover:1.33M

Market Cap:555.22M

PE:15.40

High:11.550

Open:11.550

Low:10.900

Close:11.730

52wk High:13.933

52wk Low:9.365

Shares:50.20M

Float Shares:41.32M

Volume Ratio:1.15

T/O Rate:0.29%

Dividend:0.05

Dividend Rate:0.45%

EPS(TTM):0.718

EPS(LYR):0.718

ROE:16.30%

ROA:11.37%

PB:2.31

PE(LYR):15.40

Loading ...

Overview Company News Filings

Concept

Pharmaceutical Companies-0.85%

Capital Flow

Inflow:

Outflow:

News

Exploring 3 High Growth Tech Stocks in Australia

Simply Wall St.

Clinuvel Pharmaceuticals Anticipates Health Canada Marketing Authorization Decision For Vitiligo Treatment Candidate in H2

MT Newswires Live

ASX Growth Companies With High Insider Ownership January 2026

Simply Wall St.

Does Clinuvel’s New VLRX-L Injectable Platform Shift the Long-Term Pipeline Narrative for ASX:CUV?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CUV.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CUV.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","market":"AU","secType":"STK","nameCN":"CLINUVEL PHARMACEUTICALS LTD","latestPrice":11.06,"timestamp":1770354720000,"preClose":11.73,"halted":0,"volume":120210,"delay":0,"changeRate":-0.057118499573742536,"nameEN":"CLINUVEL PHARMACEUTICALS LTD","floatShares":41318955,"shares":50200740,"eps":0.717999,"marketStatus":"Market Closed","change":-0.67,"latestTime":"02-06 16:12:00 AEDT","open":11.55,"high":11.55,"low":10.9,"amount":1332628,"amplitude":0.055413,"askPrice":11.75,"askSize":12110,"bidPrice":11,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":0.717999,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770591600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":11.73,"dividendRate":0.004521,"openAndCloseTimeList":[[1770332400000,1770354000000]],"volumeRatio":1.1492395781999007,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","floatShares":41318955,"roa":"11.37%","roe":"16.30%","lyrEps":0.717999,"volumeRatio":1.1492395781999007,"shares":50200740,"dividePrice":0.05,"high":11.55,"amplitude":0.055413,"preClose":11.73,"low":10.9,"week52Low":9.365,"pbRate":"2.31","psRate":"5.84","week52High":13.933,"institutionHeld":0,"latestPrice":11.06,"committee":-0.847445,"eps":0.717999,"divideRate":0.004521,"volume":120210,"delay":0,"ttmEps":0.717999,"open":11.55,"prevYearClose":12.46,"prevWeekClose":11,"prevMonthClose":11,"prevQuarterClose":12.46,"fiveDayClose":11,"twentyDayClose":12.64,"sixtyDayClose":11.02,"dividendPayoutRate":0.06921842705277628,"dividendFrequency":"A","dividendGrowthYears":5,"dividendGrowthRate":0,"fiveYearAvgDividendRate":0.0025824359172833843},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CUV.AU\",params:#limit:5,,,undefined,":[{"date":"2025-09-04","symbol":"CUV.AU","amount":0.05,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-05","defaultRemindTime":1756944000000,"name":"CLINUVEL PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-19","payableDate":"2025-09-05","currency":"AUD","dateTimestamp":1756908000000,"payDate":"2025-09-19"},{"date":"2025-08-28","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756339200000,"name":null,"time":"","dateTimestamp":1756303200000,"actualEps":null},{"date":"2025-02-26","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null},{"date":"2024-09-05","symbol":"CUV.AU","amount":0.05,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2024-09-06","defaultRemindTime":1725494400000,"name":"CLINUVEL PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-20","payableDate":"2024-09-06","currency":"AUD","dateTimestamp":1725458400000,"payDate":"2024-09-20"},{"date":"2024-08-29","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724889600000,"name":null,"time":"","dateTimestamp":1724853600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CUV.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-03","recordDate":"2020-09-04","paymentDate":"2020-09-18","value":0.025,"currency":"AUD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-17","value":0.025,"currency":"AUD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-09-21","value":0.04,"currency":"AUD"},{"executeDate":"2023-09-05","recordDate":"2023-09-06","paymentDate":"2023-09-20","value":0.05,"currency":"AUD"},{"executeDate":"2024-09-05","recordDate":"2024-09-06","paymentDate":"2024-09-20","value":0.05,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CUV.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2608307388","title":"Exploring 3 High Growth Tech Stocks in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2608307388","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608307388?lang=en_us&edition=fundamental","pubTime":"2026-02-04 03:06","pubTimestamp":1770145565,"startTime":"0","endTime":"0","summary":"The Australian stock market is experiencing a potential rebound, with shares expected to rise by over 1% following recent sell-offs, as investors anticipate the Reserve Bank of Australia's impending interest rate hike decision. In this dynamic environment, high-growth tech stocks can offer intriguing opportunities for investors seeking innovation and resilience amidst economic shifts and evolving global strategies.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/exploring-3-high-growth-tech-stocks-in-australia-11","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/exploring-3-high-growth-tech-stocks-in-australia-11","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","XKO.AU","BK7094","CUV.AU","XAO.AU","BK7067","CGS.AU","XJO.AU","PYC.AU"],"gpt_icon":0},{"id":"2608839722","title":"Clinuvel Pharmaceuticals Anticipates Health Canada Marketing Authorization Decision For Vitiligo Treatment Candidate in H2","url":"https://stock-news.laohu8.com/highlight/detail?id=2608839722","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608839722?lang=en_us&edition=fundamental","pubTime":"2026-02-02 11:47","pubTimestamp":1770004022,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  anticipates the receipt of Health Canada's marketing authorization decision for its drug candidate Scenesse for the treatment of vitiligo in the second half of 2026, according to a Monday Australian bourse filing.The company also expects to report top-line preclinical results from its controlled-release liquid injectable platform candidate, VLRX-L, study in the first half, the filing said.The company's shares shed about 1% in recent Monday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","CUV.AU","BK7508"],"gpt_icon":0},{"id":"2607545890","title":"ASX Growth Companies With High Insider Ownership January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2607545890","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607545890?lang=en_us&edition=fundamental","pubTime":"2026-01-30 03:09","pubTimestamp":1769713763,"startTime":"0","endTime":"0","summary":"As the Australian market navigates a period of uncertainty with flat trading and cautious investor sentiment following the U.S. Federal Reserve's recent decision to hold interest rates steady, attention turns to how local indices will respond to upcoming announcements from the Reserve Bank of Australia. In this environment, growth companies with high insider ownership can be particularly appealing, as they often signal strong confidence from those who know the business best and may offer...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-companies-with-high-insider-ownership-january-202-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-companies-with-high-insider-ownership-january-202-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["REG.AU","XKO.AU","BK7067","BK7036","P1E.AU","TTT.AU","WZR.AU","NWF.AU","BK7508","BK7016","BK7506","XAO.AU","CUV.AU","SKS.AU","BK7095","BK7093","BK7117","XJO.AU","3DP.AU","BK7113","AEM.AU","BK7017","BK7142","SEA.AU","BK7023","LM8.AU","EIQ.AU","AV1.AU","BK7116"],"gpt_icon":0},{"id":"2604744915","title":"Does Clinuvel’s New VLRX-L Injectable Platform Shift the Long-Term Pipeline Narrative for ASX:CUV?","url":"https://stock-news.laohu8.com/highlight/detail?id=2604744915","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604744915?lang=en_us&edition=fundamental","pubTime":"2026-01-17 01:30","pubTimestamp":1768584634,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals has recently begun dosing in a preclinical study of its VLRX-L controlled-release liquid injectable peptide platform, marking the first formal evaluation of this next-generation delivery technology.\nThis step signals an effort to build a broader pipeline based on in-house intellectual property that could diversify the business beyond its existing treatment franchise if development progresses successfully.\nWe’ll now explore how advancing the proprietary VLRX-L...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/does-clinuvels-new-vlrx-l-injectable-platform-shift-the-long","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/does-clinuvels-new-vlrx-l-injectable-platform-shift-the-long","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","VLRX","CUV.AU","BK7067"],"gpt_icon":0}],"pageSize":4,"totalPage":11,"pageCount":1,"totalSize":44,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CUV.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"Pharmaceutical Companies","bkCode":"BK7508","id":"package_au_concept_yyswg","changeRate":-0.008451}]}}